May 29, 2025
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 14, 2025
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
May 01, 2025
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
Mar 10, 2025
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
Jan 07, 2025
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Nov 11, 2024
Kodiak Sciences to Participate in Upcoming Investor Conferences
Sep 17, 2024
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
May 29, 2024
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
May 15, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
May 02, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Mar 26, 2024
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
Jan 30, 2024
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
Feb 02, 2021
Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
Nov 20, 2020
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nov 17, 2020
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
Nov 16, 2020
Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
Nov 16, 2020
Kodiak Sciences Announces Proposed Offering of Common Stock
Nov 12, 2020
Kodiak Sciences to Present at Upcoming Conferences
Nov 11, 2020
Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting